Docetaxel-incluced subungual hemorrhage

Dermatology

Volumn 194, Issue 4, 1997, Pages 419-420

  Vanhooteghem, O ^a   Andre J ^a   Vindevoghel, A ^b   Vandenbossche, L ^b   Vandeveire, A ^b   Song, M ^a  

^a HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^b Saintc Elisabeth Hospital   (Belgium)

Author keywords

Docetaxel; Drug reaction; Nail; Subungual hemorrhage; Taxotere

Indexed keywords

DOCETAXEL;

ARTICLE; BLEEDING; BREAST CANCER; CASE REPORT; DRUG USE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; NAIL DISEASE; OVARY CANCER; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NAIL DISEASES; PACLITAXEL; TAXOIDS;

EID: 0030760783     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000246166     Document Type: Article

References (10)

1. Chevalier B. Fumoleau P. Kerbrat P. Dieras V. Roche H, Krakowski I. Azli N. Bayssas M, Lentz MA. Van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995:13: 314-322.
2. Francis P. Schneider J. Hann L. Balmaceda C. Barakat R. Phillips M. Hakes T: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994:12:2301-2308.
3. Fossella FV, Lee JS. Murphy WK. Lipp-man SM. Calayag M. Pang A. Chasen M. Shin DM, Glisson B. Bcnner S: Phase II study of docetaxel for recurrent or metastatic nonsmall-cell lung cancer. J Clin Oncol 1994:12: 1238-1244.
4. Zimmerman GC. Keeling JH. Lowry M. Medina J. Von Hoff DD. Burris HA: Prevention of docetaxel-induced erythrodysesthesia with local hypothermia letterl. J Natl Cancer Inst 1994:86:557-558.
5. Zimmerman GC. Keeling JH. Burris HA. Cook G. Irvin R. Kuhn J, McCollough ML. Von Hoff DD: Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995:131:202-206.
6. Guillaume JC. Carp E. Rougier P. Charpentier P, André P. Carde P. Avril MF: Effets secondaires cutanéo-muqueux des perfusions continues de 5-fluorouracile. Ann Dermatol Vénéréol 1988:115:1167-1169.
7. Burgdof W. Gilmore W. Ganick R: Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Vied 1982:97:61-62.
8. Ortoli JC. Bensaid L. Ollivaud L. Bosq J. Armand JP. Avril MF: Toxidermie au docetaxel (Taxotere). Ann Dermatol Vénéréol 1994:121 (suppl 1):S94-S95.
9. Daniel CR. Scher RK: Nail changes secondary to systemic drugs or ingestants. J Am Acad Dermatol 1984;10:250-258.
10. Bégaud B. Evrcux JC. Jouglard J. Lasier G: Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France. Thérapie 1985:40:111-118